Eledon Pharmaceuticals, Inc. 8-K

What Happened

• Eledon Pharmaceuticals, Inc. announced on May 13, 2026 that it issued a press release reporting results for the quarter ended March 31, 2026. The company furnished the press release as Exhibit 99.1 to a Current Report on Form 8-K (Item 2.02: Results of Operations and Financial Condition). The report was signed by CEO David‑Alexandre C. Gros, M.D.

Key Details

• Filing date: May 13, 2026 (Form 8-K furnished to the SEC).
• Reported period: Quarter ended March 31, 2026.
• Exhibit: Press release attached as Exhibit 99.1.
• Form items: Item 2.02 (results of operations) and Item 9.01 (exhibits/interactive data) were referenced; the release was furnished (not filed).

Why It Matters

• This 8-K furnishes Eledon’s quarterly results and is the company’s formal SEC disclosure of its Q1 2026 earnings/financial condition; investors should read the attached press release for specific revenue, expense, cash position, and operational metrics.
• Because the press release was furnished (rather than filed), it is provided for investor transparency but may have different legal treatment than a filed disclosure.